Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief Executive Anne Wojcicki seeks to stabilize her money-losing business. As part of the restructuring,
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe is ending its cancer research program and slashing over 200 jobs
Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a result, while “substantially” lowering operating expe
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe Succumbs to Layoffs, Cutting 40% of Its Workforce
Me has announced layoffs at the organization. It will also discontinue its therapy programs and clinical trials to refocus the business.
23andMe announces workforce cut of 40% before the holidays
DNA site 23andMe is now announcing a big cut just before the holidays – the latest setback for the struggling South San Francisco startup.
23andMe cuts 40% of its workforce, discontinues all therapy programs
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring program.
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
Genetic testing company 23andMe announced that it would be slashing its workforce by 40%, which would mean rendering 200 employees jobless, as part of its restructuring initiative to cut costs. In a press release on Monday,
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
49m
23andMe warns of ‘substantial doubt’ over its survival without new funding
Genetics-testing company 23andMe has warned there is “substantial doubt” over its continued survival unless it raises new ...
STAT
1h
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
2h
23andMe 2Q Loss Narrows After Disclosing Restructuring
23andMe posted a narrower loss in its fiscal second quarter, the day after announcing it would cut 40% of its workforce and discontinue its pipeline of therapeutics.
FierceBiotech
18h
23andMe shutters cancer drug research programs, lays off 40% of staff
23andMe
is shutting down its therapeutics development division and plans to seek out buyers to find a new home for its ...
3h
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, ...
3h
on MSN
23andMe’s stock turns lower after company posts its latest quarterly loss
Me Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported fiscal second-quarter earnings, a ...
Yahoo News UK
7h
23andMe, supported by Richard Branson, announces major layoffs and strategy shift following data breach
23andMe
, the genetic testing firm backed by Richard Branson's VG Acquisition Corp, has announced plans to lay off 200 ...
14h
on MSN
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback